Melatonin supplementation shows potential in lupus

Investigators may have illuminated a new therapeutic agent to treat lupus.

In a literature review published in Current Molecular Pharmacology, investigators examined the results of both preclinical and clinical studies focused on melatonin — a known anti-inflammatory and antioxidant agent.

The investigators discovered that melatonin was capable of reducing inflammation and oxidative stress in preclinical models. Further, clinical studies involving patients with systemic lupus erythematosus who received melatonin supplementation corroborated declines in oxidative stress as well as demonstrated decreased disease activity and antifibrotic effects.

As a result, the investigators hypothesized that receipt of melatonin supplements could help minimize the risk of renal damage in this patient population. Nonetheless, more studies are needed to better understand the benefits of melatonin as an adjunctive therapy in lupus.

Read more: Current Molecular Pharmacology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.